et_marketsabout 4 hours ago
BULLISH(90%)
buy
Mankind Pharma shares in focus as Morgan Stanley initiates coverage with Overweight call. Check target, upside
Read original source+61.3
Market Impact Score
-100 Bearish+100 Bullish
AI Analysis
Analyst coverage initiation with a positive rating often acts as a catalyst for stock price movement, especially for a prominent pharma company like Mankind Pharma. The sector is generally defensive.
Trading Insight
Long position in Mankind Pharma, targeting the ₹2,500 level, with a stop-loss below recent support levels.
Quick check: MANKIND neutral (+2.0% 1d), SUNPHARMA bullish bias (+2.7% 1d).
Key Evidence
- •Morgan Stanley initiated coverage on Mankind Pharma with an Overweight rating.
- •Target price of ₹2,500, implying 23% upside.
- •Brokerage expects steady revenue growth and strong EPS expansion.
- •Domestic recovery and BSV integration are supporting factors.
- •Recent share price weakness due to near-term pressures in acute therapies.
Affected Stocks
MANKINDMankind Pharma Ltd
Positive
Morgan Stanley initiated coverage with an 'Overweight' rating and a significant upside target, citing strong growth prospects.
Sectors:pharma
AI-powered analysis by
Anadi Algo News